M Anthony Moody

List of Publications by Year
in descending order

169	13,149	22153	27406
papers	citations	59 h-index	106 g-index

179	179	179	12330
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14216-14221.	7.1	402
2	Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. Journal of Virology, 2011, 85, 9998-10009.	3.4	393
3	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. Immunity, 2013, 38, 176-186.	14.3	374
4	Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9019-9024.	7.1	371
5	Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. Journal of Experimental Medicine, 2018, 215, 1571-1588.	8.5	366
6	Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family. Journal of Virology, 2012, 86, 11521-11532.	3.4	357
7	A rhesus macaque model of Asian-lineage Zika virus infection. Nature Communications, 2016, 7, 12204.	12.8	353
8	Influence of HLA-C Expression Level on HIV Control. Science, 2013, 340, 87-91.	12.6	352
9	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. Cell, 2016, 165, 449-463.	28.9	305
10	Neonatal Meningitis: What Is the Correlation Among Cerebrospinal Fluid Cultures, Blood Cultures, and Cerebrospinal Fluid Parameters?. Pediatrics, 2006, 117, 1094-1100.	2.1	286
11	Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials. Journal of Infectious Diseases, 2012, 206, 431-441.	4.0	273
12	Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. Cell, 2014, 158, 481-491.	28.9	266
13	Human Responses to Influenza Vaccination Show Seroconversion Signatures and Convergent Antibody Rearrangements. Cell Host and Microbe, 2014, 16, 105-114.	11.0	246
14	High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. Journal of Virological Methods, 2009, 158, 171-179.	2.1	235
15	InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell, 2021, 184, 4203-4219.e32.	28.9	228
16	Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 264-269.	7.1	227
17	Staged induction of HIV-1 glycanâ€“dependent broadly neutralizing antibodies. Science Translational Medicine, 2017, 9, .	12.4	212
18	An HIV-1 gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 Serum. Journal of Virology, 2011, 85, 7029-7036.	3.4	210

#	Article	IF	Citations
19	Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. Journal of Experimental Medicine, 2011, 208, 2237-2249.	8.5	198
20	Diversion of HIV-1 vaccineâ€“induced immunity by gp41-microbiota cross-reactive antibodies. Science, 2015, 349, aab1253.	12.6	191
21	HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. Journal of Virology, 2014, 88, 7715-7726.	3.4	169
22	T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response. JCI Insight, 2017, 2, .	5.0	164
23	A Novel Variant Marking HLA-DP Expression Levels Predicts Recovery from Hepatitis B Virus Infection. Journal of Virology, 2012, 86, 6979-6985.	3.4	162
24	H3N2 Influenza Infection Elicits More Cross-Reactive and Less Clonally Expanded Anti-Hemagglutinin Antibodies Than Influenza Vaccination. PLoS ONE, 2011, 6, e25797.	2.5	158
25	Viral Receptor-Binding Site Antibodies with Diverse Germline Origins. Cell, 2015, 161, 1026-1034.	28.9	151
26	Polyclonal B Cell Differentiation and Loss of Gastrointestinal Tract Germinal Centers in the Earliest Stages of HIV-1 Infection. PLoS Medicine, 2009, 6, e1000107.	8.4	143
27	Antibody polyspecificity and neutralization of HIV-1: A hypothesis. Human Antibodies, 2006, 14, 59-67.	1.5	142
28	Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies. Cell Host and Microbe, 2014, 16, 304-313.	11.0	137
29	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nature Communications, 2017, 8, 15711.	12.8	137
30	Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting. PLoS ONE, 2011, 6, e23532.	2.5	137
31	Dual-Affinity Re-Targeting proteins direct T cellâ€“mediated cytolysis of latently HIV-infected cells. Journal of Clinical Investigation, 2015, 125, 4077-4090.	8.2	124
32	Immune perturbations in HIV-1â€“infected individuals who make broadly neutralizing antibodies. Science Immunology, 2016, 1, aag0851.	11.9	120
33	Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses. PLoS Pathogens, 2016, 12, e1005817.	4.7	119
34	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Science Immunology, 2017, 2, .	11.9	119
35	Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 168-173.	7.1	113
36	Functional interrogation and mining of natively paired human VH:VL antibody repertoires. Nature Biotechnology, 2018, 36, 152-155.	17.5	109

#	Article	IF	Citations
37	Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Human Antibodies, 2005, 14, 59-67.	1.5	109
38	Human Immunodeficiency Virus Type 1 gp41 Antibodies That Mask Membrane Proximal Region Epitopes: Antibody Binding Kinetics, Induction, and Potential for Regulation in Acute Infection. Journal of Virology, 2008, 82, 115-125.	3.4	108
39	HIV-1 Envelope gp41 Antibodies Can Originate from Terminal Ileum B Cells that Share Cross-Reactivity with Commensal Bacteria. Cell Host and Microbe, 2014, 16, 215-226.	11.0	105
40	Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity Maturation. Frontiers in Immunology, 2014, 5, 170.	4.8	104
41	Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. Nature Medicine, 2016, 22, 1465-1469.	30.7	104
42	Traumatic Lumbar Punctures in Neonates. Pediatric Infectious Disease Journal, 2008, 27, 1047-1051.	2.0	97
43	A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy. BMC Infectious Diseases, 2015, 15, 479.	2.9	97
44	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. Cell Reports, 2017, 21, 3681-3690.	6.4	97
45	An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. Journal of Clinical Investigation, 2014, 124, 1835-1843.	8.2	93
46	Pyrrole oxidation and protein cross-linking as necessary steps in the development of .gamma.-diketone neuropathy. Chemical Research in Toxicology, 1988, 1, 179-185.	3.3	88
47	Initiation of immune toleranceâ€“controlled HIV gp41 neutralizing B cell lineages. Science Translational Medicine, 2016, 8, 336ra62.	12.4	86
48	Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Current Opinion in Immunology, 2011, 23, 383-390.	5.5	85
49	Epitope Specificity of Human Immunodeficiency Virus-1 Antibody Dependent Cellular Cytotoxicity [ADCC] Responses. Current HIV Research, 2013, 11, 378-387.	0.5	82
50	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Science Translational Medicine, 2017, 9, .	12.4	81
51	Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies Identified from a Patient with 2F5-Like Antibodies. Journal of Virology, 2011, 85, 11401-11408.	3.4	80
52	Toll-Like Receptor 7/8 (TLR7/8) and TLR9 Agonists Cooperate To Enhance HIV-1 Envelope Antibody Responses in Rhesus Macaques. Journal of Virology, 2014, 88, 3329-3339.	3.4	80
53	RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses. Cell, 2018, 175, 387-399.e17.	28.9	78
54	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. Immunity, 2019, 50, 677-691.e13.	14.3	77

#	Article	IF	Citations
55	Induction of Plasma (TRAIL), TNFR-2, Fas Ligand, and Plasma Microparticles after Human Immunodeficiency Virus Type 1 (HIV-1) Transmission: Implications for HIV-1 Vaccine Design. Journal of Virology, 2008, 82, 7700-7710.	3.4	76
56	HIV-1 gp120 Vaccine Induces Affinity Maturation in both New and Persistent Antibody Clonal Lineages. Journal of Virology, 2012, 86, 7496-7507.	3.4	76
57	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Nature Communications, 2017, 8, 1732.	12.8	76
58	Effect of antipyretic analgesics on immune responses to vaccination. Human Vaccines and Immunotherapeutics, 2016, 12, 2391-2402.	3.3	73
59	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. Cell Reports, 2017, 18, 2175-2188.	6.4	69
60	HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. Mucosal Immunology, 2013, 6, 692-703.	6.0	68
61	Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth. Nature Immunology, 2020, 21, 199-209.	14.5	68
62	Maternal HIV-1 envelopeâ€“specific antibody responses and reduced risk of perinatal transmission. Journal of Clinical Investigation, 2015, 125, 2702-2706.	8.2	68
63	HIV-1 Envelope Induces Memory B Cell Responses That Correlate with Plasma Antibody Levels after Envelope gp120 Protein Vaccination or HIV-1 Infection. Journal of Immunology, 2009, 183, 2708-2717.	0.8	67
64	Immunogenic Stimulus for Germline Precursors of Antibodies that Engage the Influenza Hemagglutinin Receptor-Binding Site. Cell Reports, 2015, 13, 2842-2850.	6.4	67
65	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host and Microbe, 2015, 18, 354-362.	11.0	66
66	Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved. Immunity, 2014, 41, 909-918.	14.3	65
67	Progress in HIV-1 vaccine development. Journal of Allergy and Clinical Immunology, 2014, 134, 3-10.	2.9	62
68	HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends in Microbiology, 2012, 20, 532-539.	7.7	61
69	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. Immunity, 2018, 49, 1162-1174.e8.	14.3	61
70	Infectious Virion Capture by HIV-1 gp120-Specific IgG from RV144 Vaccinees. Journal of Virology, 2013, 87, 7828-7836.	3.4	59
71	Immunologic characteristics of <scp>HIV</scp>â€infected individuals who make broadly neutralizing antibodies. Immunological Reviews, 2017, 275, 62-78.	6.0	58
72	Infant HIV Type 1 gp120 Vaccination Elicits Robust and Durable Anti-V1V2 Immunoglobulin G Responses and Only Rare Envelope-Specific Immunoglobulin A Responses. Journal of Infectious Diseases, 2015, 211, 508-517.	4.0	57

#	Article	IF	Citations
73	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell, 2021, 184, 2955-2972.e25.	28.9	57
74	The PIG-A Mutation and Absence of Glycosylphosphatidylinositol-Linked Proteins Do Not Confer Resistance to Apoptosis in Paroxysmal Nocturnal Hemoglobinuria. Blood, 1998, 92, 2541-2550.	1.4	56
75	CD4-Mimetic Small Molecules Sensitize Human Immunodeficiency Virus to Vaccine-Elicited Antibodies. Journal of Virology, 2014, 88, 6542-6555.	3.4	55
76	Influenza and Antibody-Dependent Cellular Cytotoxicity. Frontiers in Immunology, 2019, 10, 1457.	4.8	55
77	Isolation of a Monoclonal Antibody That Targets the Alpha-2 Helix of gp120 and Represents the Initial Autologous Neutralizing-Antibody Response in an HIV-1 Subtype C-Infected Individual. Journal of Virology, 2011, 85, 7719-7729.	3.4	54
78	Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. Journal of Virology, 2017, 91, .	3.4	52
79	Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce Î²-chemokines. Journal of Experimental Medicine, 2010, 207, 763-776.	8.5	51
80	Primary Infection by a Human Immunodeficiency Virus with Atypical Coreceptor Tropism. Journal of Virology, 2011, 85, 10669-10681.	3.4	51
81	Severe Acute Respiratory Syndrome Coronavirus 2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) Study. Clinical Infectious Diseases, 2021, 73, e2875-e2882.	5.8	51
82	Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome. Retrovirology, 2012, 9, 89.	2.0	50
83	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. Science, 2021, 371, .	12.6	49
84	Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. Science Translational Medicine, 2021, 13, .	12.4	49
85	A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. Nature Communications, 2018, 9, 2363.	12.8	46
86	The Humoral Response to HIVâ€1: New Insights, Renewed Focus. Journal of Infectious Diseases, 2010, 202, S315-S322.	4.0	45
87	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. Cell Reports, 2016, 14, 43-54.	6.4	45
88	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. Journal of Virology, 2018, 92, .	3.4	45
89	Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents. JCI Insight, 2021, 6, .	5.0	45
90	NMR-Derived Solution Conformations of a Hybrid Synthetic Peptide Containing Multiple Epitopes of Envelope Protein gp120 from the RF Strain of Human Immunodeficiency Virus. Biochemistry, 1994, 33, 2055-2062.	2.5	44

#	Article	IF	Citations
91	A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. Cell Reports, 2016, 15, 1505-1513.	6.4	43
92	Capacity for Infectious HIV-1 Virion Capture Differs by Envelope Antibody Specificity. Journal of Virology, 2014, 88, 5165-5170.	3.4	41
93	Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. Journal of Virology, 2018, 92, .	3.4	39
94	Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. Journal of Virology, 2016, 90, 5031-5046.	3.4	38
95	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathogens, 2017, 13, e1006182.	4.7	38
96	Antigenâ€specific B cell detection reagents: Use and quality control. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 1086-1092.	1.5	37
97	B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Trends in Molecular Medicine, 2011, 17, 108-116.	6.7	37
98	HIV-1 Specific IgA Detected in Vaginal Secretions of HIV Uninfected Women Participating in a Microbicide Trial in Southern Africa Are Primarily Directed Toward gp120 and gp140 Specificities. PLoS ONE, 2014, 9, e101863.	2.5	36
99	Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women. Vaccine, 2018, 36, 6354-6360.	3.8	35
100	Conformational Preferences of a Chimeric Peptide HIV-1 Immunogen from the C4â^'V3 Domains of gp120 Envelope Protein of HIV-1 CAN0A Based on Solution NMR:â€‰ Comparison to a Related Immunogenic Peptide from HIV-1 RF. Biochemistry, 1996, 35, 5158-5165.	2.5	34
101	A comparison of neonatal Gram-negative rod and Gram-positive cocci meningitis. Journal of Perinatology, 2006, 26, 111-114.	2.0	34
102	Key mutations stabilize antigenâ€binding conformation during affinity maturation of a broadly neutralizing influenza antibody lineage. Proteins: Structure, Function and Bioinformatics, 2015, 83, 771-780.	2.6	34
103	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. EBioMedicine, 2016, 12, 196-207.	6.1	34
104	Isolation of HIV-1-Neutralizing Mucosal Monoclonal Antibodies from Human Colostrum. PLoS ONE, 2012, 7, e37648.	2.5	30
105	Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. PLoS ONE, 2017, 12, e0179597.	2.5	29
106	Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. Virology, 2009, 394, 91-98.	2.4	28
107	Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques. Vaccine Journal, 2017, 24, .	3.1	28
108	Immune checkpoint modulation enhances HIV-1 antibody induction. Nature Communications, 2020, 11, 948.	12.8	27

#	Article	IF	Citations
109	Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. Viruses, 2015, 7, 5443-5475.	3.3	26
110	Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants. MBio, 2020, 11, .	4.1	25
111	The human fetal lymphocyte lineage: identification by CD27 and LIN28B expression in B cell progenitors. Journal of Leukocyte Biology, 2013, 94, 991-1001.	3.3	24
112	Leukopak PBMC sample processing for preparing quality control material to support proficiency testing programs. Journal of Immunological Methods, 2014, 409, 99-106.	1.4	24
113	Restricted isotype, distinct variable gene usage, and high rate of gp120 specificity of HIV-1 envelope-specific B cells in colostrum compared with those in blood of HIV-1-infected, lactating African women. Mucosal Immunology, 2015, 8, 316-326.	6.0	23
114	Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. Journal of Virology, 2016, 90, 4951-4965.	3.4	23
115	V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. Cell Reports, 2018, 25, 3123-3135.e6.	6.4	23
116	HIV Type 1 V3 Region Primer-Induced Antibody Suppression Is Overcome by Administration of C4-V3 Peptides as a Polyvalent Immunogen. AIDS Research and Human Retroviruses, 1995, 11, 211-221.	1.1	22
117	Age-Related Changes in the Nasopharyngeal Microbiome Are Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Symptoms Among Children, Adolescents, and Young Adults. Clinical Infectious Diseases, 2022, 75, e928-e937.	5.8	22
118	Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. Cell Reports, 2020, 30, 1553-1569.e6.	6.4	21
119	HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. Journal of Virology, 2017, 91, .	3.4	20
120	Innovations in HIV-1 Vaccine Design. Clinical Therapeutics, 2020, 42, 499-514.	2.5	20
121	Functional, Non-Clonal IgMa-Restricted B Cell Receptor Interactions with the HIV-1 Envelope gp41 Membrane Proximal External Region. PLoS ONE, 2009, 4, e7215.	2.5	20
122	Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. Journal of Virology, 2017, 91, .	3.4	19
123	Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. Journal of Virology, 2020, 94, .	3.4	19
124	HIV vaccine delayed boosting increases Env variable region 2â€“specific antibody effector functions. JCI Insight, 2020, 5, .	5.0	18
125	Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery. Cancer Immunology, Immunotherapy, 2016, 65, 171-180.	4.2	16
126	Predictive value of cerebrospinal fluid parameters in neonates with intraventricular drainage devices. Journal of Neurosurgery: Pediatrics, 2007, 107, 209-212.	1.3	15

#	Article	IF	Citations
127	Polychromatic plots: Graphical display of multidimensional data. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 868-874.	1.5	15
128	Plasmablast Response to Primary Rhesus Cytomegalovirus (CMV) Infection in a Monkey Model of Congenital CMV Transmission. Vaccine Journal, 2017, 24, .	3.1	15
129	Differential immune imprinting by influenza virus vaccination and infection in nonhuman primates. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	15
130	Lack of B Cell Dysfunction Is Associated with Functional, gp120-Dominant Antibody Responses in Breast Milk of Simian Immunodeficiency Virus-Infected African Green Monkeys. Journal of Virology, 2013, 87, 11121-11134.	3.4	13
131	Increased expression of anti-apoptosis genes in peripheral blood cells from patients with paroxysmal nocturnal hemoglobinuria. Molecular Genetics and Metabolism, 2003, 78, 291-294.	1.1	12
132	Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques. Npj Vaccines, 2020, 5, 36.	6.0	12
133	Eliminating antibody polyreactivity through addition of Nâ€linked glycosylation. Protein Science, 2015, 24, 1019-1030.	7.6	11
134	Functional Homology for Antibody-Dependent Phagocytosis Across Humans and Rhesus Macaques. Frontiers in Immunology, 2021, 12, 678511.	4.8	11
135	Nuclear Magnetic Resonance Analysis of Solution Conformations in C4-V3 Hybrid Peptides Derived from Human Immunodeficiency Virus (HIV) Type 1 gp120: Relation to Specificity of Peptide-Induced Anti-HIV Neutralizing Antibodies. Journal of Virology, 1999, 73, 746-750.	3.4	11
136	Enhanced Antibody Responses to an HIV-1 Membrane-Proximal External Region Antigen in Mice Reconstituted with Cultured Lymphocytes. Journal of Immunology, 2014, 192, 3269-3279.	0.8	10
137	Parental Approach to the Prevention and Management of Fever and Pain Following Childhood Immunizations: A Survey Study. Clinical Pediatrics, 2017, 56, 435-442.	0.8	10
138	Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques. JCI Insight, 2016, 1, e88522.	5.0	10
139	Necrotizing Fasciitis Caused by Haemophilus influenzae Type E in a 17-Year-Old Girl With Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2010, 16, 49-50.	0.9	9
140	Allylic substitution/rearrangement of cannabinoids with trimethylsilyl bromide. Tetrahedron Letters, 1992, 33, 3443-3446.	1.4	8
141	Modulation of HIV-1 immunity by adjuvants. Current Opinion in HIV and AIDS, 2014, 9, 242-249.	3.8	8
142	Antibodies for prevention of mother-to-child transmission of HIV-1. Current Opinion in HIV and AIDS, 2015, 10, 177-182.	3.8	8
143	Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys. Journal of Virology, 2015, 89, 9485-9498.	3.4	8
144	Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice. Journal of Immunology, 2017, 198, 1047-1055.	0.8	7

#	Article	IF	Citations
145	HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers. Scientific Reports, 2019, 9, 10165.	3.3	7
146	HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. Journal of Immunology, 2016, 197, 4663-4673.	0.8	6
147	Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial. MBio, 2020, 11, .	4.1	6
148	HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth. Scientific Reports, 2021, 11, 14494.	3.3	6
149	Extracellular Loops of the Treponema pallidum FadL Orthologs TP0856 and TP0858 Elicit IgG Antibodies and IgG⁺-Specific B-Cells in the Rabbit Model of Experimental Syphilis. MBio, 2022, 13, .	4.1	6
150	Frequent Development of Broadly Neutralizing Antibodies in Early Life in a Large Cohort of Children With Human Immunodeficiency Virus. Journal of Infectious Diseases, 2022, 225, 1731-1740.	4.0	5
151	Clonal analysis of human anti-V3 monoclonal antibodies selected by a V3 tetramer. Human Antibodies, 2013, 21, 65-73.	1.5	4
152	Intra-seasonal antibody repertoire analysis of a subject immunized with an MF59Â®-adjuvanted pandemic 2009 H1N1 vaccine. Vaccine, 2018, 36, 5325-5332.	3.8	4
153	Right-Sided Endocarditis from Staphylococcus Lugdunensis in a Patient with Tetralogy of Fallot. Gastroenterology Insights, 2019, 11, 7872.	1.2	3
154	The PIG-A Mutation and Absence of Glycosylphosphatidylinositol-Linked Proteins Do Not Confer Resistance to Apoptosis in Paroxysmal Nocturnal Hemoglobinuria. Blood, 1998, 92, 2541-2550.	1.4	3
155	Infants' diminished response to DTaP vaccine is associated with exposure to organophosphate esters. Science of the Total Environment, 2022, 837, 155782.	8.0	3
156	Simultaneous Detection of Antigen-Specific IgG- and IgM-Secreting Cells with a B Cell Fluorospot Assay. Cells, 2012, 1, 15-26.	4.1	2
157	Induction of Neutralizing Responses against Autologous Virus in Maternal HIV Vaccine Trials. MSphere, 2020, 5, .	2.9	2
158	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. PLoS Pathogens, 2021, 17, e1009624.	4.7	2
159	P04-45. Characterization of the plasma cell repertoire in acute HIV-1 infection (AHI). Retrovirology, 2009, 6, .	2.0	1
160	Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAXÂ® B/E in RV144 Vaccinees. AIDS Research and Human Retroviruses, 2014, 30, A36-A36.	1.1	1
161	Strength through Organization: Classifying Antibody Activity against EBOV. Cell Host and Microbe, 2018, 24, 185-186.	11.0	1
162	Vaccine Development: Steps to Approval of an Investigational Vaccine. North Carolina Medical Journal, 2021, 82, 141-144.	0.2	1

#	Article	IF	Citations
163	Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s. Frontiers in Immunology, 2021, 12, 787603.	4.8	1
164	Different adjuvanted pediatric HIV envelope vaccines induced distinct plasma antibody responses despite similar B cell receptor repertoires in infant rhesus macaques. PLoS ONE, 2021, 16, e0256885.	2.5	1
165	CD27+ Developing B Cells are Common in Human Fetal Liver. Journal of Allergy and Clinical Immunology, 2012, 129, AB12.	2.9	0
166	Antibody lineages with evidence of somatic hypermutation persisting for >4 years in a South African subject with broad neutralizing activity. Retrovirology, 2012, 9, .	2.0	0
167	Isolation of a clonal lineage of IgA broadly neutralizing antibodies from a chronically infected Tanzanian subject. Retrovirology, 2012, 9, .	2.0	0
168	Vaccine-induced ADCC-mediating antibodies target unique and overlapping envelope epitopes. Retrovirology, 2012, 9, .	2.0	0
169	Microbial Vaccine Development. , 2013, , 1119-1128.		0